Dupilumab Provides Clinically Meaningful Responses in Children Aged 6–11 Years With Severe Atopic Dermatitis: Post-hoc Analysis Results From a Phase III Trial
mediaposted on 2023-05-26, 01:39 authored by Adis Journals on behalf of:, Elaine C Siegfried, Michael J. Cork, Norito Katoh, Haixin Zhang, Chien-Chia Chuang, Ryan B. Thomas, Ana B. Rossi, Sonya L. Cyr, Annie Zhang
The above video abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2023